NYSE:BHC Bausch Health Companies - BHC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bausch Health Companies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.23 -0.05 (-0.69%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$7.02▼$7.2550-Day Range$7.16▼$9.8552-Week Range$4.00▼$23.97Volume4.42 million shsAverage Volume4.81 million shsMarket Capitalization$2.62 billionP/E RatioN/ADividend YieldN/APrice Target$10.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Bausch Health Companies MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside46.6% Upside$10.60 Price TargetShort InterestBearish7.70% of Float Sold ShortDividend StrengthN/ASustainability-1.42Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$2,721 Sold Last QuarterProj. Earnings Growth10.59%From $3.21 to $3.55 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector237th out of 989 stocksPharmaceutical Preparations Industry99th out of 480 stocks 3.0 Analyst's Opinion Consensus RatingBausch Health Companies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.60, Bausch Health Companies has a forecasted upside of 46.6% from its current price of $7.23.Amount of Analyst CoverageBausch Health Companies has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.70% of the float of Bausch Health Companies has been sold short.Short Interest Ratio / Days to CoverBausch Health Companies has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Bausch Health Companies has recently increased by 15.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBausch Health Companies does not currently pay a dividend.Dividend GrowthBausch Health Companies does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBausch Health Companies has received a 55.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Allergy eye drops", "Anti-diarrheal and intestinal anti-inflammatory medication (A07)", "Laxatives", and "Intraocular lenses" products. See details.Environmental SustainabilityThe Environmental Impact score for Bausch Health Companies is -1.42. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Bausch Health Companies this week, compared to 3 articles on an average week.Search InterestOnly 68 people have searched for BHC on MarketBeat in the last 30 days. This is a decrease of -1% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Bausch Health Companies to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bausch Health Companies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,721.00 in company stock.Percentage Held by Insiders13.75% of the stock of Bausch Health Companies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.99% of the stock of Bausch Health Companies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Bausch Health Companies are expected to grow by 10.59% in the coming year, from $3.21 to $3.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bausch Health Companies is -11.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bausch Health Companies is -11.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBausch Health Companies has a PEG Ratio of 0.12. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBausch Health Companies has a P/B Ratio of 10.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bausch Health Companies (NYSE:BHC) StockBausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.Read More Receive BHC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter. Email Address BHC Stock News HeadlinesMarch 21, 2023 | americanbankingnews.comBausch Health Companies Inc. (NYSE:BHC) Given Average Recommendation of "Hold" by AnalystsMarch 17, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Bausch Health Companies (NYSE:BHC)March 25, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 16, 2023 | americanbankingnews.comBausch Health Companies Inc. (NYSE:BHC) Sees Large Growth in Short InterestMarch 8, 2023 | msn.comBausch Health Stock Rose 24.5% Last Month: Can it Keep Going?March 1, 2023 | finance.yahoo.comBausch Health Announces Changes to its Board of DirectorsFebruary 25, 2023 | seekingalpha.comBausch Health Companies Inc. (BHC) Q4 2022 Earnings Call TranscriptFebruary 24, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Bausch Health Companies (BHC)March 25, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 23, 2023 | finanznachrichten.deBausch Health Companies Inc: Bausch Health Announces Fourth-Quarter and Full-Year 2022 ResultsFebruary 23, 2023 | finance.yahoo.comBausch + Lomb Full Year 2022 Earnings: EPS Misses ExpectationsFebruary 23, 2023 | finance.yahoo.comBausch Health Announces Fourth-Quarter and Full-Year 2022 ResultsFebruary 22, 2023 | finance.yahoo.comDrug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & MoreFebruary 19, 2023 | finance.yahoo.comPositive week for Bausch Health Companies Inc. (NYSE:BHC) institutional investors who lost 60% over the past yearFebruary 15, 2023 | finance.yahoo.comBausch + Lomb names ex-CEO Brent Saunders as CEO, replacing Joseph Papa and stock jumps 6.5%February 13, 2023 | finanznachrichten.deBausch Health Companies Inc: Salix Announces 2023 Gastrointestinal Health Scholars ProgramFebruary 13, 2023 | finance.yahoo.comSalix Announces 2023 Gastrointestinal Health Scholars ProgramFebruary 1, 2023 | finance.yahoo.comBausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23January 31, 2023 | marketwatch.comBausch Health Cos. Inc. stock falls Tuesday, underperforms marketJanuary 23, 2023 | reuters.comBHC.TO - | Stock Price & Latest News | ReutersJanuary 14, 2023 | nasdaq.comMarch 3rd Options Now Available For Bausch Health Companies (BHC)January 9, 2023 | finance.yahoo.comBausch Health Companies (NYSE:BHC) shareholders are up 19% this past week, but still in the red over the last three yearsDecember 30, 2022 | cnbc.comThese stocks were our best and worst performers in the fourth quarterDecember 15, 2022 | marketwatch.comBausch Health Cos. Inc. stock outperforms market despite losses on the dayDecember 2, 2022 | finanznachrichten.deBausch Health Companies Inc: Bausch Health Wins DUOBRII and BRYHALI Patent Infringement CaseDecember 1, 2022 | finance.yahoo.comSalix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care ProviderNovember 26, 2022 | finance.yahoo.comIs There An Opportunity With Bausch + Lomb Corporation's (NYSE:BLCO) 45% Undervaluation?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BHC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter. Email Address BHC Company Calendar Last Earnings8/02/2021Today3/25/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:BHC CUSIPN/A CIK885590 Webwww.bauschhealth.com Phone(514) 744-6792Fax514-744-6272Employees19,900Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.60 High Stock Price Forecast$15.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+46.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E Ratio2.25 P/E Growth0.12Net Income$-225,000,000.00 Net Margins-2.77% Pretax Margin-1.59% Return on Equity553.04% Return on Assets4.08% Debt Debt-to-Equity Ratio78.21 Current Ratio1.08 Quick Ratio0.80 Sales & Book Value Annual Sales$8.12 billion Price / Sales0.32 Cash Flow$6.57 per share Price / Cash Flow1.10 Book Value$0.72 per share Price / Book10.04Miscellaneous Outstanding Shares361,870,000Free Float312,111,000Market Cap$2.62 billion OptionableOptionable Beta1.00 Key ExecutivesThomas J. AppioChief Executive Officer & DirectorMirza DautbegovicChief Operating Officer & Senior Vice PresidentTom G. VadakethChief Financial Officer & Executive Vice PresidentTage RamakrishnaChief Medical Officer, President-R&DSeana-Lyn CarsonExecutive Vice President & General CounselKey CompetitorsAxsome TherapeuticsNASDAQ:AXSMRevance TherapeuticsNASDAQ:RVNCMyovant SciencesNYSE:MYOVUltragenyx PharmaceuticalNASDAQ:RAREBlueprint MedicinesNASDAQ:BPMCView All CompetitorsInsiders & InstitutionsSeana CarsonSold 292 sharesTotal: $2,721.44 ($9.32/share)Parallax Volatility Advisers L.P.Bought 744,600 shares on 2/27/2023Ownership: 0.000%NatixisBought 7,817,975 shares on 2/24/2023Ownership: 4.371%Northwestern Mutual Wealth Management Co.Sold 4,720 shares on 2/21/2023Ownership: 0.006%Alliancebernstein L.P.Bought 27,368 shares on 2/16/2023Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions BHC Stock - Frequently Asked Questions Should I buy or sell Bausch Health Companies stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares. View BHC analyst ratings or view top-rated stocks. What is Bausch Health Companies' stock price forecast for 2023? 4 analysts have issued twelve-month price targets for Bausch Health Companies' stock. Their BHC share price forecasts range from $6.00 to $15.00. On average, they anticipate the company's share price to reach $10.60 in the next year. This suggests a possible upside of 46.6% from the stock's current price. View analysts price targets for BHC or view top-rated stocks among Wall Street analysts. How have BHC shares performed in 2023? Bausch Health Companies' stock was trading at $6.28 at the beginning of the year. Since then, BHC stock has increased by 15.1% and is now trading at $7.23. View the best growth stocks for 2023 here. Are investors shorting Bausch Health Companies? Bausch Health Companies saw a increase in short interest in February. As of February 28th, there was short interest totaling 27,480,000 shares, an increase of 15.8% from the February 13th total of 23,740,000 shares. Based on an average trading volume of 5,710,000 shares, the short-interest ratio is presently 4.8 days. Approximately 7.7% of the shares of the stock are short sold. View Bausch Health Companies' Short Interest. When is Bausch Health Companies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our BHC earnings forecast. How were Bausch Health Companies' earnings last quarter? Bausch Health Companies Inc. (NYSE:BHC) issued its earnings results on Monday, August, 2nd. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.95 by $0.02. The business earned $2.10 billion during the quarter, compared to the consensus estimate of $2.12 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 553.04% and a negative net margin of 2.77%. What guidance has Bausch Health Companies issued on next quarter's earnings? Bausch Health Companies updated its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.45 billion-$4.60 billion, compared to the consensus revenue estimate of $8.31 billion. What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO? 43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Bausch Health Companies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC). What is Bausch Health Companies' stock symbol? Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC." Who are Bausch Health Companies' major shareholders? Bausch Health Companies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Goldentree Asset Management LP (5.88%), Franklin Resources Inc. (4.89%), Natixis (4.37%), National Bank of Canada FI (3.63%), Laurion Capital Management LP (2.88%) and Lombard Odier Asset Management USA Corp (0.00%). Insiders that own company stock include Amy B Wechsler, Christina Ackermann, Holdings LP Valueact, John Paulson, Joseph F Gordon, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Seana Carson, Steven D Miller and William D Humphries. View institutional ownership trends. How do I buy shares of Bausch Health Companies? Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bausch Health Companies' stock price today? One share of BHC stock can currently be purchased for approximately $7.23. How much money does Bausch Health Companies make? Bausch Health Companies (NYSE:BHC) has a market capitalization of $2.62 billion and generates $8.12 billion in revenue each year. The company earns $-225,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. How many employees does Bausch Health Companies have? The company employs 19,900 workers across the globe. How can I contact Bausch Health Companies? Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The official website for the company is www.bauschhealth.com. The company can be reached via phone at (514) 744-6792, via email at ir@bauschhealth.com, or via fax at 514-744-6272. This page (NYSE:BHC) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.